{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T15:30:19Z","timestamp":1649086219088},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.eururo.2015.03.029","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T15:38:16Z","timestamp":1428939496000},"page":"263-264","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Maintenance Bacillus Calmette-Gu\u00e9rin Therapy: The Search for the Optimum Treatment Schedule Continues"],"prefix":"10.1016","volume":"68","author":[{"given":"Richard J.","family":"Sylvester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.03.029_bib0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0065","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0070","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0085","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin treatment of non-muscle invasive bladder cancer: a critical evaluation of the evidence","volume":"64","author":"Ehdaie","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0115","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non\u2013muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1464-410X.2012.11754.x","article-title":"Bacillus Calmette-Guerin immunotherapy for genitourinary cancer","volume":"112","author":"Gandhi","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.03.029_bib0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2011.09.026","article-title":"Markers predicting response to bacillus Calmette-Gu\u00e9rin immunotherapy in high-risk bladder cancer patients: a systematic review","volume":"61","author":"Zuiverloon","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.03.029_bib0105","doi-asserted-by":"crossref","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2015.03.029_bib0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2011.03.051","article-title":"Bacillus Calmette-Gu\u00e9rin without maintenance therapy for high-risk non\u2013muscle-invasive bladder cancer","volume":"60","author":"Herr","year":"2011","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815002481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815002481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T14:31:16Z","timestamp":1537713076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815002481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0302283815002481"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.03.029","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance Bacillus Calmette-Gu\u00e9rin Therapy: The Search for the Optimum Treatment Schedule Continues","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.02.040","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}